Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan A Fletcher

Showing results (151-160 of 205) with videos related to

Pageof 21
Sort By:
The Journal of Pathology|February 2, 2012
ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumourBadreddin Edris, Iñigo Espinosa, Thomas Mühlenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumorMichael C Heinrich, Robert G Maki, Christopher L Corless, et al.
The American Journal of Surgical Pathology|September 24, 2010
Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small sizeSabrina Rossi, Daniela Gasparotto, Luisa Toffolatti, et al.
International Journal of Cancer|July 22, 2014
Combined DNA methylation and gene expression profiling in gastrointestinal stromal tumors reveals hypomethylation of SPP1 as an independent prognostic factorFlorian Haller, Jitao David Zhang, Evgeny A Moskalev, et al.
Cancer|March 31, 2021
Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomasInga-Marie Schaefer, Meijun Z Lundberg, Elizabeth G Demicco, et al.
Cancer Discovery|September 25, 2020
Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase DomainSusanne Grunewald, Lillian R Klug, Thomas Mühlenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology GroupMichael C Heinrich, Kouros Owzar, Christopher L Corless, et al.
Plos One|October 12, 2013
Membrane-to-nucleus signaling links insulin-like growth factor-1- and stem cell factor-activated pathwaysYujiro Hayashi, David T Asuzu, Simon J Gibbons, et al.
Oncogene|October 8, 2021
E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumorAlfonso García-Valverde, Jordi Rosell, Sergi Sayols, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2014
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patientsAndrew P Garner, Joseph M Gozgit, Rana Anjum, et al.
Pageof 21

Showing results (151-160 of 205) with videos related to

Sort By:
Pageof 21
The Journal of Pathology|February 2, 2012
ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumourBadreddin Edris, Iñigo Espinosa, Thomas Mühlenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumorMichael C Heinrich, Robert G Maki, Christopher L Corless, et al.
The American Journal of Surgical Pathology|September 24, 2010
Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small sizeSabrina Rossi, Daniela Gasparotto, Luisa Toffolatti, et al.
International Journal of Cancer|July 22, 2014
Combined DNA methylation and gene expression profiling in gastrointestinal stromal tumors reveals hypomethylation of SPP1 as an independent prognostic factorFlorian Haller, Jitao David Zhang, Evgeny A Moskalev, et al.
Cancer|March 31, 2021
Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomasInga-Marie Schaefer, Meijun Z Lundberg, Elizabeth G Demicco, et al.
Cancer Discovery|September 25, 2020
Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase DomainSusanne Grunewald, Lillian R Klug, Thomas Mühlenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology GroupMichael C Heinrich, Kouros Owzar, Christopher L Corless, et al.
Plos One|October 12, 2013
Membrane-to-nucleus signaling links insulin-like growth factor-1- and stem cell factor-activated pathwaysYujiro Hayashi, David T Asuzu, Simon J Gibbons, et al.
Oncogene|October 8, 2021
E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumorAlfonso García-Valverde, Jordi Rosell, Sergi Sayols, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2014
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patientsAndrew P Garner, Joseph M Gozgit, Rana Anjum, et al.
Pageof 21